Multiple myeloma Clinical Trials

Recruiting multiple myeloma studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat multiple myeloma. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting multiple myeloma studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting multiple myeloma trials

Within

MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma

for Multiple Myeloma

1 site in Burlington

Sponsor: University of Vermont Medical Center

Sex: All·Age: 18+

Code: NCT07783607

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

for Multiple Myeloma

1 site in Seattle

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18 - 70

Code: NCT04579523·Phase 1

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

for Recurrent Multiple Myeloma

1 site in Philadelphia

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07463807·Phase 1, Phase 2

Apply to this trial

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

for Waldenstrom Macroglobulinaemia

Sponsor: Anne Louise Tølbøll Sørensen

Sex: All·Age: 18+

Code: NCT07474961·Phase 4

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

for Multiple Myeloma

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 18 - 80

Code: NCT03271632·Phase 1, Phase 2

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

for Multiple Myeloma

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 18 - 80

Code: NCT06429150·Phase 1, Phase 2

INfections in Patients Treated With CAR-T

for Relapsed Multiple Myeloma

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Sex: All·Age: 18+

Code: NCT07713511

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

for Relapse Multiple Myeloma

1 site in Milwaukee

Sponsor: Medical College of Wisconsin

Sex: All·Age: 18 - 80

Code: NCT07221032·Phase 1

Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging

for Monoclonal Gammopathy

Sponsor: University of Zurich

Sex: All·Age: 18+

Code: NCT07624760

A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

for Multiple Myeloma

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT07609706·Phase 1

A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

for Multiple Myeloma

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT07742527·Phase 1

BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

for Multiple Myeloma

1 site in Milwaukee

Sponsor: Medical College of Wisconsin

Sex: All·Age: 18+

Code: NCT07009899·Phase 2

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

for Multiple Myeloma

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Sex: All·Age: 18 - 75

Code: NCT07648459·Phase 2

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

1 site in La Crosse

Sponsor: PrECOG, LLC.

Sex: All·Age: 18 - 79

Code: NCT07285239·Phase 3

Apply to this trial

BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

for Non-Hodgkin Lymphoma

1 site in Cleveland

Sponsor: Luminary Therapeutics

Sex: All·Age: 18 - 75

Code: NCT07679919·Phase 1

Musculoskeletal Ultrasound in Patients With Hematologic Malignancies

for Hematologic Neoplasms

Sponsor: Assiut University

Sex: All·Age: 18+

Code: NCT07785505

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

for Multiple Myeloma

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07665450·Phase 3

TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

for Relapse Multiple Myeloma

Sponsor: Montefiore Medical Center

Sex: All·Age: 18+

Code: NCT07720843·Phase 1

Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma

for Recurrent Multiple Myeloma

1 site in Sacramento

Sponsor: University of California, Davis

Sex: All·Age: 18 - 65·Accepts healthy volunteers

Code: NCT07759102·Phase 1

Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)

for Cardiotoxicity

1 site in Minneapolis

Sponsor: University of Minnesota

Sex: All·Age: 18+

Code: NCT07776964

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

for Multiple Myeloma

1 site in St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT07200089·Phase 1

Apply to this trial

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

for Multiple Myeloma (MM)

5 sites incl. Denver

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT07637578·Phase 2

Apply to this trial

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

for Recurrent Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06948084·Phase 2

A Open-Label Phase in Participants With Multiple Myeloma

for Multiple Myeloma

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Sex: All·Age: 18+

Code: NCT07764861·Phase 2

Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry

for Multiple Myeloma

Sponsor: Odense University Hospital

Sex: All·Age: 18+

Code: NCT07691034

Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

for Multiple Myeloma

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT07614360·Phase 2

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

for Multiple Myeloma

3 sites in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT07247097·Phase 2

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

for Cytokine Release Syndrome

1 site in Columbus

Sponsor: Naresh Bumma

Sex: All·Age: 18+

Code: NCT07657312·Phase 2

Apply to this trial

Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells

for Multiple Myeloma

Sponsor: The Affiliated People's Hospital of Ningbo University

Sex: All·Age: 18+

Code: NCT07732712·Phase 2, Phase 3

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

for Multiple Myeloma

1 site in New York

Sponsor: Shambavi Richard

Sex: All·Age: 18+

Code: NCT07727668·EARLY_Phase 1

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

for Multiple Myeloma

1 site in Boston

Sponsor: Andrew Hantel, MD

Sex: All·Age: 18+

Code: NCT07341867·Phase 1

Apply to this trial

A Clinical Study of SHR-5421 in Patients With Multiple Myeloma

for Multiple Myeloma

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Sex: All·Age: 18+

Code: NCT07652281·Phase 1

Apply to this trial

Delayed Toxicities Post-CAR-T

for Multiple Myeloma

3 sites incl. San Francisco

Sponsor: Icahn School of Medicine at Mount Sinai

Sex: All·Age: 18+

Code: NCT07665307

Apply to this trial

MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Sex: All·Age: 18+

Code: NCT07409454·Phase 2

Apply to this trial

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

for Multiple Myeloma

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07569757·Phase 3

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

for Multiple Myeloma

1 site in Beverly Hills

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07589634·Phase 2

Apply to this trial

Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

for Multiple Myeloma

Sponsor: Shanghai Zhongshan Hospital

Sex: All·Age: 18+

Code: NCT07663253

Apply to this trial

GMMG-HD11/DSMM XXI/64007957MMY3010

for Multiple Myeloma

Sponsor: University of Heidelberg Medical Center

Sex: All·Age: 18 - 70

Code: NCT07671287·Phase 3

Pre-malignant States to Hematologic Malignancies in Firefighters

for Clonal Hematopoiesis of Indeterminate Potential

1 site in Charlotte

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: 40 - 49·Accepts healthy volunteers

Code: NCT06870760

Apply to this trial

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

for Multiple Myeloma

7 sites incl. Duarte

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT07555938·Phase 3

Apply to this trial

Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

for Multiple Myeloma

Sponsor: Chinese PLA General Hospital

Sex: All·Age: 18 - 75

Code: NCT07620275·Phase 1

Apply to this trial

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

3 sites in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18 - 75

Code: NCT07624513·Phase 3

A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

for Multiple Myeloma

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT07490613·Phase 1

Apply to this trial

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

for Multiple Myeloma

Sponsor: iOMEDICO AG

Sex: All·Age: 18+

Code: NCT07559799

Apply to this trial

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

for Multiple Myeloma

1 site in Iowa City

Sponsor: Christopher Strouse

Sex: All·Age: 18+

Code: NCT07581704·Phase 1

Apply to this trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

35 sites incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07518186·Phase 3

Apply to this trial

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

for Cytokine Release Syndrome

1 site in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT07499128

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

for Multiple Myeloma

Sponsor: Shanghai Zhongshan Hospital

Sex: All·Age: 18+

Code: NCT07638683·Phase 2

Apply to this trial

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

for Relapse Multiple Myeloma

1 site in Madison

Sponsor: Natalie Callander

Sex: All·Age: 18+

Code: NCT07479979·Phase 1, Phase 2

Apply to this trial

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

for Multiple Myeloma

1 site in Milwaukee

Sponsor: Medical College of Wisconsin

Sex: All·Age: 18 - 80

Code: NCT05976555·Phase 1

Apply to this trial

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

for Multiple Myeloma

3 sites incl. Brooklyn

Sponsor: NYU Langone Health

Sex: All·Age: 18+

Code: NCT07567014·Phase 2

Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research

for Multiple Myeloma

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Sex: All·Age: 18+

Code: NCT07403071

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

for Recurrent B-Cell Non-Hodgkin Lymphoma

1 site in Columbus

Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All·Age: 18+

Code: NCT07609030

Apply to this trial

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

for Multiple Myeloma

1 site in Nashville

Sponsor: Eden Biltibo

Sex: All·Age: 18 - 70

Code: NCT07485647·Phase 2

Apply to this trial

Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial

for Multiple Myeloma

Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Sex: All·Age: 18 - 70

Code: NCT07542418

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

for Non-hodgkin Lymphoma

8 sites incl. Basking Ridge

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT07249528

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

for Multiple Myeloma

12 sites incl. Los Alamitos

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT07227311·Phase 2

Apply to this trial

Halt Aging in Survivors of Blood Cancers

for Hematological Malignancy

1 site in Omaha

Sponsor: University of Nebraska

Sex: All·Age: 50+

Code: NCT07292272

Apply to this trial

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

for Multiple Myeloma

1 site in Miami

Sponsor: University of Miami

Sex: All·Age: 18+

Code: NCT07446777

Apply to this trial

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Sponsor: Fortvita Biologics (USA)Inc.

Sex: All·Age: 18+

Code: NCT07336472·Phase 1, Phase 2

New trials in Boston, MA?

Pick a condition and we'll email you once a week when a new study starts recruiting in Boston, MA. Unsubscribe anytime.

Multiple myeloma clinical trials — common questions

Are multiple myeloma clinical trials free to join?

Yes. Participating in a multiple myeloma clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a multiple myeloma clinical trial?

Each multiple myeloma study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a multiple myeloma trial near me?

Use the location controls above. We'll show recruiting multiple myeloma trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many multiple myeloma trials are recruiting right now?

We're currently tracking roughly 217 recruiting multiple myeloma trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Multiple myeloma trials by city

Boston, MA Birmingham, AL Duarte, CA Miami, FL Milwaukee, WI San Francisco, CA Chicago, IL Seattle, WA Denver, CO Los Angeles, CA Columbus, OH Jacksonville, FL

Related specialties

Oncology Blood cancer